Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tandem Diabetes Care filings document the company’s insulin delivery business, Nasdaq-listed common stock, operating results, governance matters, and capital structure. Recent 8-K reports furnish quarterly and annual financial results, guidance-related disclosures, and product or regulatory events tied to its diabetes technology portfolio.
The filing record also includes proxy materials for annual meeting voting, director elections, executive compensation, equity awards, and board committee matters. Material-event filings describe the company’s completed 0.00% convertible senior notes offering, related indenture terms, and FDA clearance for the SteadiSet wearable infusion set.
Tandem Diabetes Care (TNDM) furnished a press release reporting its financial results for the quarter ended September 30, 2025. The release is provided as Exhibit 99.1 and incorporated by reference in this report.
The company notes that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and therefore is not subject to Section 18 liability of the Exchange Act or automatically incorporated into other filings unless specifically referenced.
Tandem Diabetes Care (TNDM) reported insider activity by EVP & Chief Operating Officer Jean-Claude Kyrillos. On 10/15/2025, 3,636 shares of common stock were acquired at $0 upon the vesting and settlement of restricted stock units (RSUs), coded “M.” The company withheld 1,301 shares at $14.75 (code “F”) to satisfy tax obligations; no shares were sold.
Following these transactions, the officer directly owns 22,384 common shares. The RSUs were granted on July 15, 2024 under the company’s 2023 Long‑Term Incentive Plan. Each RSU represents the right to receive one share or cash at the company’s discretion. The award vests 33% on 7/15/2025, with the remainder vesting in eight equal quarterly installments thereafter.
Rick A. Carpenter, Chief Technology Officer of Tandem Diabetes Care, reported transactions on 09/15/2025 affecting his holdings of TNDM common stock. 406 restricted stock units (RSUs) vested and were recorded as acquired under code M with a $0 price, leaving 22,773 shares beneficially owned after the transaction. Separately, 207 shares were disposed of under code F(1) at $12.09 per share, leaving 22,566 shares reported as beneficially owned following that disposition. The filing states that the Company withheld shares to satisfy tax withholding on RSU vesting and that no shares were sold to cover taxes. The RSUs were originally awarded on 12/15/2021 under the 2013 Stock Incentive Plan and vest 25% on 12/15/2022 with the remainder vesting in twelve equal quarterly installments.
Insider Form 4 for TNDM (Mark D. Novara) reports transactions on 09/15/2025 related to vested restricted stock units (RSUs) awarded under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan. The filing shows 7,415 RSUs withheld to satisfy tax withholding on vesting (transaction code M) at no sales proceeds, and a separate disposition of 3,866 shares for $12.09 per share (transaction code F(1)). After these actions the reporting person beneficially owned 32,348 shares of common stock. The RSUs were granted 12/15/2023 and vest 33% on 12/15/2024 with the remainder in eight equal quarterly installments.
Mark D. Novara, EVP & Chief Commercial Officer of Tandem Diabetes Care, Inc. (TNDM), reported changes in his beneficial ownership on 08/15/2025. The filing shows withholding of shares to satisfy tax obligations related to vested restricted stock units (RSUs) awarded May 23, 2024; the company withheld shares rather than selling them. The report lists an acquisition entry of 76 common shares (code M) at no cash price and a disposition entry of 40 common shares (code F) at $10.82. After these transactions, Novara beneficially owns 28,799 common shares (direct) per the Form 4 figures. The RSU award vests 33% on 5/15/2025 with the remainder vesting in eight equal quarterly installments.
Susan M. Morrison, EVP & Chief Administrative Officer of Tandem Diabetes Care, Inc. (TNDM), reported equity transactions dated 08/15/2025 on Form 4. The filing shows vesting of restricted stock units (RSUs) awarded under the 2023 Long-Term Incentive Plan: 1,503 RSUs and 1,097 RSUs were settled (transaction code M) with an acquisition price of $0 for each award. To satisfy tax withholding on the vesting, the company withheld 430 and 314 shares respectively at a withholding price of $10.82 per share; the filer states explicitly that no shares were sold. The Form indicates the transactions were reported by an attorney-in-fact on 08/19/2025. The filing itemizes the share movements and confirms the RSU grant and vesting schedule terms referenced in the explanation section of the Form.
John F. Sheridan, President & CEO and director of Tandem Diabetes Care, Inc. (TNDM), reported RSU vesting and related share withholding to cover taxes on transactions dated 08/15/2025. The filing shows vested restricted stock units (RSUs) settled into 5,471 and 5,982 shares respectively, increasing underlying ownership; the company withheld 2,779 and 3,038 shares in two separate withholding dispositions at $10.82 per share to satisfy tax obligations. After these transactions, Sheridan beneficially owned between 109,019 and 115,001 shares across reported lines. The RSUs were awarded under the 2023 Long-Term Incentive Plan and vest per the schedules described in the filing.
Rick A. Carpenter, Chief Technology Officer of Tandem Diabetes Care, Inc. (TNDM), reported multiple equity transactions on 08/15/2025. Two grants of restricted stock units (RSUs) vested, resulting in 1,437 and 898 shares being issued at $0 as part of long-term incentive awards. To satisfy tax withholding on vesting, the company withheld 730 and 457 shares; the withheld shares were not sold. After the reported transactions, the filing shows common stock beneficial ownership balances changing between 21,926 and 22,824 shares and derivative (RSU) balances of 4,311 and 6,281 shares as reported in the table. The RSUs were awarded under the 2023 Long-Term Incentive Plan and vest on a 33% initial schedule with subsequent quarterly installments.
Leigh A. Vosseller, EVP & Chief Financial Officer of Tandem Diabetes Care, Inc. (TNDM), reported multiple transactions on 08/15/2025 related to vested restricted stock units (RSUs) and tax-withholding events. The filing shows two RSU vesting events that resulted in the acquisition of 1,503 and 1,495 shares each (total 2,998 shares) at $0 price upon vesting, increasing her direct holdings. The report also records share withholdings to satisfy tax obligations: 538 and 535 shares withheld at $10.82 per share. Following the transactions, total directly held common stock positions reported are 4,509 and 10,469 shares tied to two RSU awards, and 35,723–36,258 shares in various lines; additionally, 25,580 shares are held indirectly in the Leigh A. Vosseller Trust. The form was signed by an attorney-in-fact on 08/19/2025.
Tandem Diabetes Care insider Shannon M. Hansen reported multiple transactions on 08/15/2025 related to restricted stock units (RSUs) and common stock. The filing shows vesting-driven acquisitions: 531, 1,437 and 1,097 RSUs converted into common stock (total underlying 3,065 shares added to direct holdings) and corresponding increases in direct common stock ownership to a reported 7,677 shares of derivative-backed common stock and 19,102 shares of direct common stock at various steps. Several entries show shares withheld to satisfy tax withholding at $10.82 per share; no open-market sales were reported. The securities held indirectly are in the Shannon M. Hansen Trust.